Cefsulodin
 | |
| Systematic (IUPAC) name | |
|---|---|
|
4-(aminocarbonyl)-1-[((6R,7R)-2-carboxy-8-oxo-7-{[phenyl(sulfo)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]pyridinium | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Identifiers | |
| CAS Number |
52152-93-9  |
| ATC code | J01DD03 |
| PubChem | CID 5284530 |
| ChemSpider |
4447588 |
| UNII |
OV42LHE42B |
| KEGG |
D02005 |
| ChEMBL |
CHEMBL1617285  |
| Chemical data | |
| Formula | C22H21N4O8S2+ |
| Molar mass | 533.556 g/mol |
| |
| |
| (what is this?) (verify) | |
Cefsulodin is a third-generation cephalosporin antibiotic with specific activity against Pseudomonas aeruginosa. It has no significant activity against other Gram-negative bacteria and very limited activity against Gram-positive bacteria and anaerobic bacteria. Cefsulodin was first synthesized and patented by the Takeda Pharmaceutical Company in 1977. In 2002, Takeda stopped production of cefsulodin. Many years of low-stability cefsulodin production has led to a widespread reduction of laboratory and research uses. Current attempts (i.e. IDEXX Laboratories) of increasing purity and stability of cefsulodin center around recrystallization. Typically, the process entails: Cefsulodin is dissolved in an organic solvent, sodium ions, water, or any mixture thereof, then subsequently recrystallized through separation of the unwanted fraction. Recently, TOKU-E has found the main cause of cefsulodin instability stems from one key impurity in 7-aminocephalosporanic acid, a raw material used in the synthesis of cefsulodin. To produce high-purity, high-stability cefsulodin, TOKU-E uses industrial HPLC to remove significant quantities of this impurity in 7-ACA and thus produces ultrapure, ultrastable, and ultrapotent cefsulodin.[1]
General use
Cefuslodin is most commonly used in cefsulodin-irgasan-novobiocin agar to select for Yersinia microorganisms.[2] This agar is most often used in water and beverage testing.
Susceptibility data
The following represents MIC susceptibility data for various P. aeruginosa strains.
- Pseudomonas aeruginosa PA13 (resistant strain): 32 μg/ml
- Pseudomonas aeruginosa (wild-type, susceptible): 4 - 8 μg/ml
References
- ↑ , TOKU-E Technical Application Sheet.
- ↑ "BAM Media M35: Cefsulodin-Irgasan Novobiocin Agar or Yersinia Selective Agar". Retrieved 2 September 2012.
- ↑ http://antibiotics.toku-e.com/antimicrobial_474.html
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||